Go Pro
NASDAQ:SYBX

Synlogic Q3 2024 Earnings Report

Synlogic logo
$1.11 0.00 (0.00%)
As of 10/2/2026

Synlogic EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.17
One Year Ago EPS
N/A

Synlogic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synlogic Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Synlogic's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Synlogic Earnings Headlines

Elon will prove them wrong again
Elon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no driver in major U.S. cities. Veteran tech investor James Altucher says Musk is applying the same playbook to a new project he calls his infinite money glitch, expected to launch October 21. Altucher, who has tracked tech breakthroughs for nearly four decades, calls this the biggest one he has ever covered.tc pixel
Synlogic Challenges Nasdaq Delisting Notice
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX) is a biotechnology company focused on developing medicines based on synthetic biology. Its platform engineers probiotic bacteria, primarily strains of Escherichia coli, to perform specific therapeutic functions inside the gastrointestinal tract, such as consuming disease-associated metabolites or producing beneficial compounds.

The company’s development programs have targeted rare metabolic disorders. Notable candidates have included SYNB1618 and SYNB1934 for phenylketonuria, a condition involving impaired processing of phenylalanine, and SYNB8802 for hyperoxaluria, a disorder characterized by excessive oxalate production. Synlogic has also investigated its technology in other metabolic diseases and therapeutic areas.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Synlogic advanced its programs through clinical development with an initial focus on the United States and potential applications in international markets. The company’s research has centered on using engineered living medicines to address conditions that may be difficult to treat with conventional pharmaceutical approaches.

View Synlogic Profile